menu

History

1969Established with capital of JPY 5 million; started manufacture of first aid bandages
1972Established the Hydrogel Patch Department
1975Started manufacture of Sankyo Pap (OTC use)
1978Started manufacture of Sankyo Neo Pap (Prescription use)
1979Completed the GMP certified Himata Plant (Plant No. 1)
1985Completed the General Research Center
1988Completed the Himata Plant (Plant No. 2)
Acquired marketing authorization for the transdermal absorption patch
Adofeed® (the present Adofeed® Pap 40mg for prescription use)
1990Concluded License Agreement with UK company Boots Pharmaceuticals for development of Adofeed® in overseas market (TransAct® LAT, Targus® LAT)
1991Increased the capital to JPY 190 million
Established the Tokyo office
1994Completed the Hisagane Plant in Kamiichi
Started export to Italy and South Africa (TransAct® LAT)
1996Started export to Portugal and Pakistan (TransAct® LAT and Targus® LAT)
Started export to US market (“Pain Patch” (current ICY HOT®Patch))
1997Started export to Portugal and Pakistan (TransAct® LAT and Targus® LAT)
1998Started export to Brazil (Targus® LAT)
2000Increased capital to JPY 458.67 million
2006Acquired manufacturing and marketing authorization for Loxonin® Pap 100mg (for prescription use)
Expanded the Hisagane Plant
2008Acquired marketing authorization for Loxonin® Tape 50mg and 100mg (for prescription use)
Acquired marketing authorization for Adofeed® Pap 80mg
2011Completed the Hisagane Plant (East Plant)
2015Started export of Loxonin® Tape 50mg to China
Acquired marketing authorization for Loxonin®S Pap, Loxonin®S Tape and Loxonin®S Tape L (behind-the-counter products)
2016Ibuprofen Medicated Plaster approved for registration in 6 European countries
2017Submitted application for registration of Loxonin® Pap in countries of the ASEAN region
2018Started export of Ibuprofen Medicated Plaster for commercialization in Belgium, Ireland and UK
Ibuprofen Medicated Plaster approved for registration in 16 additional European countries
2019Ibuprofen Medicated Plaster was granted the “Product of the Year” award in UK, being the only OTC medicine to win the award in that year

Page Top

 MENU

×CLOSE

Language